Relationship between ustekinumab trough concentrations and both clinical and biological remission in patients with Crohn's disease

Lao Domínguez, Francisco Ángel; Fobelo Lozano, María José; Gutiérrez Pizarraya, Antonio; Castro Fernández, Manuel

doi:10.1016/j.gastre.2022.10.017

array:23 ["pii" => "S2444382423001487" "issn" => "24443824" "doi" => "10.1016/j.gastre.2022.10.017" "estado" => "S300" "fechaPublicacion" => "2023-10-01" "aid" => "2009" "copyright" => "Elsevier España, S.L.U.. All rights reserved" "copyrightAnyo" => "2022" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Gastroenterol Hepatol. 2023;46:631-2" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:18 [ "pii" => "S2444382423001505" "issn" => "24443824" "doi" => "10.1016/j.gastre.2022.11.005" "estado" => "S300" "fechaPublicacion" => "2023-10-01" "aid" => "2020" "copyright" => "Elsevier España, S.L.U." "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Gastroenterol Hepatol. 2023;46:633-4" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "Image of the month" "titulo" => "Spontaneous cutaneous fistula secondary to hepatic hydatidosis" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "633" "paginaFinal" => "634" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Fístula cutánea secundaria a hidatidosis hepática" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 802 "Ancho" => 988 "Tamanyo" => 103220 ] ] "descripcion" => array:1 [ "en" => "Abdominal CT with oral and intravenous contrast with multiple cystic formations in the segment V of the liver with fistulous communication between the abdominal wall and the hydatid vesiculation (red arrow)." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Miguel Sogbe, José Luis del Pozo" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Miguel" "apellidos" => "Sogbe" ] 1 => array:2 [ "nombre" => "José Luis" "apellidos" => "del Pozo" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2444382423001505?idApp=UINPBA00004N" "url" => "/24443824/0000004600000008/v2_202311101346/S2444382423001505/v2_202311101346/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S2444382423001268" "issn" => "24443824" "doi" => "10.1016/j.gastre.2023.07.002" "estado" => "S300" "fechaPublicacion" => "2023-10-01" "aid" => "1977" "copyright" => "Elsevier España, S.L.U." "documento" => "article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Gastroenterol Hepatol. 2023;46:629-30" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "Scientific letter" "titulo" => "Tofacitinib for the treatment of inflammatory condition of the ileoanal pouch refractory to infliximab" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "629" "paginaFinal" => "630" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Tofacitinib para el tratamiento de la afección inflamatoria del reservorio refractaria a infliximab" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1620 "Ancho" => 2933 "Tamanyo" => 269388 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0035" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "Evolution of haemoglobin values (g/dl) in the last two years (January 2020–May-2022)." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Marta Fortuny, Laura Gutiérrez-Rios, Eva Vayreda, Míriam Mañosa, Eugeni Domènech" "autores" => array:5 [ 0 => array:2 [ "nombre" => "Marta" "apellidos" => "Fortuny" ] 1 => array:2 [ "nombre" => "Laura" "apellidos" => "Gutiérrez-Rios" ] 2 => array:2 [ "nombre" => "Eva" "apellidos" => "Vayreda" ] 3 => array:2 [ "nombre" => "Míriam" "apellidos" => "Mañosa" ] 4 => array:2 [ "nombre" => "Eugeni" "apellidos" => "Domènech" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0210570522002096" "doi" => "10.1016/j.gastrohep.2022.08.005" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0210570522002096?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2444382423001268?idApp=UINPBA00004N" "url" => "/24443824/0000004600000008/v2_202311101346/S2444382423001268/v2_202311101346/en/main.assets" ] "en" => array:14 [ "idiomaDefecto" => true "cabecera" => "Scientific letter" "titulo" => "Relationship between ustekinumab trough concentrations and both clinical and biological remission in patients with Crohn's disease" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "631" "paginaFinal" => "632" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Francisco Ángel Lao Domínguez, María José Fobelo Lozano, Antonio Gutiérrez Pizarraya, Manuel Castro Fernández" "autores" => array:4 [ 0 => array:4 [ "nombre" => "Francisco Ángel" "apellidos" => "Lao Domínguez" "email" => array:1 [ 0 => "fralaodom@gmail.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "María José" "apellidos" => "Fobelo Lozano" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] ] ] 2 => array:3 [ "nombre" => "Antonio" "apellidos" => "Gutiérrez Pizarraya" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] ] ] 3 => array:3 [ "nombre" => "Manuel" "apellidos" => "Castro Fernández" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Hospital Universitario Virgen de Valme, Pharmacy Service, Seville, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Hospital Universitario Virgen de Valme, Digestive Medicine Service, Seville, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Relación entre las concentraciones mínimas de ustekinumab y la remisión clínica y biológica en pacientes con enfermedad de Crohn" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1983 "Ancho" => 3174 "Tamanyo" => 209025 ] ] "descripcion" => array:1 [ "en" => "A. Quartile distribution of ustekinumab levels according clinical remission. B. Ustekinumab levels according clinical remission. C. Ustekinumab levels according biological remission. D. Ustekinumab levels according clinical remission in patients without intestinal resection surgery. NS: not significant." ] ] ] "textoCompleto" => "The data about TDM of ustekinumab is still limited despite being a potential drug for it.<a class="elsevierStyleCrossRefs" href="#bib0025">1–4</a> Taking into consideration the potential benefits of TDM, the addition of ustekinumab monitoring to clinical practice could improve clinical decisions in the treatment of Crohn disease (CD) for which it is necessary to provide more data in this regard.We studied patients with CD undergoing maintenance treatment with ustekinumab who underwent at least one determination of serum ustekinumab level to provide further evidence of the correlation between them and both clinical and biological remission.All samples were classified according to disease activity at the time of level determination. Clinical remission was established through Harvey-Bradshaw index considering no disease activity when it had a value ≤4. Biological remission was based on analytical values of both CRP (<5mg/L) and CAL (<250μg/g). Sample extraction was performed just before the next administration of ustekinumab.Forty one samples from thirty seven patients were collected. Median age was 43 years (IQR: 35–52.5) and 20 patients were women. CD was located in 62.2% (N=23) in ileum-colon, 27% (N=10) in ileum and 10.8% (N=4) in colon. The profile of CD was inflammatory in 43.2%, stenosing in 32.4%, penetrating in 10.8% and stenosing-penetrating in 13.5%. Intestinal resection surgery prior to the onset of ustekinumab was present in 45.9% of the patients. In this group of patients, surgery was performed at least 1 year before its inclusion in the study.Ustekinumab was used as the third line of biological treatment in 70.3% of patients, 27% in the second and 10.3% in the fourth. The dosing regimen at the time of sample extraction was 90mg every 8 weeks (68.3%), every 7 weeks (4.9%), every 6 weeks (9.8%) and every 4 weeks (17.1%). The median treatment time was 23 months (IQR: 10–29). Eight patients (10.3%) were reinduced with an IV dose with a median time between ustekinumab reinduction and sample extraction of 34.6 weeks (IQR: 22.8–38.6). 5.4% of patients were on concomitant immunomodulatory treatment (methotrexate). Albumin serum median level was 4.47g/dL (IQR: 4.23–4.85).Trough serum concentration was determined in all patients in the maintenance phase (median of 23 months [IQR: 10-29]). No antibodies (ADA) against ustekinumab were detected in any patient. In general, there was an increasing trend in the percentage of patients in clinical remission as the serum drug level increased (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>A). In samples from patients with clinical remission, median minimum serum ustekinumab concentrations were 2.78 (IQR: 1.84–4.13)μg/mL; in the remaining samples without clinical remission the level was 2.08 (IQR: 1.05–3.5)μg/mL (p=0.337) (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>B). The CAL level was available in 68.3% of patients. In patients with biological remission, median CAL and CRP values were 116.7μg/g (IQR: 71.8–213.9) and 1.9mg/L (IQR: 1.3–3.1) respectively. In patients without remission the values were 206.4μg/g (IQR: 64.5–378.1) (p=0.595) and 3.9mg/L (IQR: 1.85–12.3) (p<0.05) respectively. Ustekinumab serum level of patients seems to be higher in those with both clinical and biological remission which is consistent with published results on literature, however these differences were statistically non-significant probably due to the low sample size (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>B and C). On the other hand, range of ustekinumab levels as quartiles has to be interpreted with caution (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>A), since the possible optimal interval to achieve clinical remission is expected to be very small when ustekinumab is administered subcutaneously and with a long period between doses.<elsevierMultimedia ident="fig0005"></elsevierMultimedia>It must be taken into account that in clinical practice conditions, the population is very heterogeneous, with different affected sites, previous lines of treatment, with or without previous surgery. Therefore, the results obtained were also analyzed by dividing them into two groups of patients, with or without intestinal resection surgery prior to ustekinumab. In patients without intestinal resection in clinical remission showed a significant higher in median trough serum drug concentrations compared to patients without clinical remission (2.77 [IQR: 2.01–4.45] vs. 1.67 [IQR: 0.58–2.06]μg/mL; p=0.005) (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>D).In conclusion, our study suggests that in CD patients without intestinal resection surgery ustekinumab serum levels may be related to clinical remission, being higher in those with clinical remission. Regarding all CD patients, ustekinumab serum levels seems to be higher in those with clinical and biological remission, but these differences did not have a statistical significance.FundingThis research has not received specific support from public sector agencies, commercial sector or non-profit entities." "textoCompletoSecciones" => array:1 [ "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0005" "titulo" => "Funding" ] 1 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "multimedia" => array:1 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1983 "Ancho" => 3174 "Tamanyo" => 209025 ] ] "descripcion" => array:1 [ "en" => "A. Quartile distribution of ustekinumab levels according clinical remission. B. Ustekinumab levels according clinical remission. C. Ustekinumab levels according biological remission. D. Ustekinumab levels according clinical remission in patients without intestinal resection surgery. NS: not significant." ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:4 [ 0 => array:3 [ "identificador" => "bib0025" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A comprehensive literature review and expert consensus statement on therapeutic drug monitoring of biologics in inflammatory bowel disease" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A.S. Cheifetz" 1 => "M.T. Abreu" 2 => "W. Afif" 3 => "R.K. Cross" 4 => "M.C. Dubinsky" 5 => "E.V. Loftus" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.14309/ajg.0000000000001396" "Revista" => array:6 [ "tituloSerie" => "Am J Gastroenterol" "fecha" => "2021" "volumen" => "116" "paginaInicial" => "2014" "paginaFinal" => "2025" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34388143" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0030" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Update on TDM (therapeutic drug monitoring) with ustekinumab, vedolizumab and tofacitinib in inflammatory bowel disease" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "S. Restellini" 1 => "W. Afif" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3390/jcm10061242" "Revista" => array:5 [ "tituloSerie" => "J Clin Med" "fecha" => "2021" "volumen" => "10" "paginaInicial" => "1242" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33802816" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0035" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pharmacokinetics and exposure response relationships of ustekinumab in patients with Crohn's disease" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "O.J. Adedokun" 1 => "Z. Xu" 2 => "C. Gasink" 3 => "D. Jacobstein" 4 => "P. Szapary" 5 => "J. Johanns" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1053/j.gastro.2018.01.043" "Revista" => array:6 [ "tituloSerie" => "Gastroenterology" "fecha" => "2018" "volumen" => "154" "paginaInicial" => "1660" "paginaFinal" => "1671" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29409871" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0040" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "D. Alsoud" 1 => "S. Vermeire" 2 => "B. Verstockt" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.coph.2020.09.002" "Revista" => array:6 [ "tituloSerie" => "Curr Opin Pharmacol" "fecha" => "2020" "volumen" => "55" "paginaInicial" => "17" "paginaFinal" => "30" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33039940" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/24443824/0000004600000008/v2_202311101346/S2444382423001487/v2_202311101346/en/main.assets" "Apartado" => array:4 [ "identificador" => "77930" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Scientific letter" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/24443824/0000004600000008/v2_202311101346/S2444382423001487/v2_202311101346/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2444382423001487?idApp=UINPBA00004N"]

ISSN: 2444-3824

Gastroenterology and Hepatology is the first journal to cover the latest advances in pathology of the gastrointestinal tract, liver, pancreas, and bile ducts, making it an indispensable tool for gastroenterologists, hepatologists, internists and general practitioners. In addition to the rigorously selected, systematically peer-reviewed manuscripts published in the research sections (Original Articles, Scientific Letters, Editorials, and Letters to the Editor), the journal also contains other important sections, such as Review Articles and Clinical Decision-Making Support, which offer in-depth reviews and updates on issues relating to the specialty.

See more Open Access Option

Indexed in:

SCIE/Journal of Citation Reports, Index Medicus/Medline, Excerpta Medica/EMBASE, SCOPUS, CANCERLIT, IBECS

Subscribe:

Impact factor

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.

© Clarivate Analytics, Journal Citation Reports 2022

Impact factor 2023

2.2

Citescore

CiteScore measures average citations received per document published.

Citescore 2023

1.5

SJR

SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

SJR 2023

0.263

SNIP

SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

SNIP 2023

0.306

View more metrics

Journal Information

Previous article | Next article

Vol. 46. Issue 8.